New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For MRK;PFE;GSK;JNJ;BMY;NVS;SHPG;ABT;CELG;SNY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | all recent news | >>
October 27, 2014
07:01 EDTMRKMerck reports Q3 EPS ex-items 90c, consensus 88c
Subscribe for More Information
06:46 EDTMRKMerck granted Breakthrough Therapy Designation for KEYTRUDA by FDA
Subscribe for More Information
06:28 EDTNVSVirbac acquires veterinary assets from Eli Lilly in U.S.
Virbac announces that it has entered into an agreement with Eli Lilly (LLY) to acquire "major" U.S. veterinary products currently marketed by Novartis (NVS) Animal Health. Eli Lilly has agreed to divest these U.S. assets in connection with the U.S. Federal Trade Commission’s review of Eli Lilly’s pending acquisition of Novartis Animal Health worldwide. Under the terms of this agreement, Virbac would acquire a combination of titles and rights for the U.S. on trademarks, marketing authorizations, patents, know-how, customer lists and other assets, related to two parasiticides for dogs including Sentinel Flavor Tabs and Sentinel Spectrum, currently marketed in the U.S. by Novartis Animal Health. In the U.S., Sentinel Flavor tabs and Sentinel Spectrum are expected to reach total revenues of approximately $90M-$100M in 2014. Adding these brands and commercial franchise to the current Virbac portfolio of products offered to veterinary clinics and pet owners in the U.S. will strengthen Virbac’s presence and penetration in the U.S. companion animal veterinary market and leverage its growth potential. The completion of this transaction is subject to approval by the Federal Trade Commission, which Virbac expects may be received in the near future. It is also conditioned on the closing of the acquisition of Novartis Animal Health by Eli Lilly and should occur shortly thereafter.
06:06 EDTSHPGShire upgraded to Outperform from Market Perform at William Blair
Subscribe for More Information
October 26, 2014
16:55 EDTSHPGShire CEO 'dumbfounded' by AbbVie's decision, Bloomberg says
Subscribe for More Information
October 24, 2014
16:02 EDTBMYOptions Update; October 24, 2014
Subscribe for More Information
13:35 EDTMRKMerck weekly volatility elevated into Q3 and outlook
Subscribe for More Information
13:31 EDTGSKEbola vaccine testing could begin in December, NY Times says
Subscribe for More Information
11:15 EDTBMYBristol-Myers says has capacity for large deal
Subscribe for More Information
10:42 EDTBMYBristol-Myers sees coming in closer to high end of FY14 EPS guidance
Subscribe for More Information
10:10 EDTBMYBristol-Myers to host conference call
Conference call to review data presented at the Chicago Multidisciplinary Symposium on Thoracic Oncology (CMSTO) will be held on October 31 at 2:30 pm. Webcast Link
08:15 EDTJNJJohnson & Johnson management to meet with JPMorgan
Meetings to be held in Chicago/Kansas City on October 29 hosted by JPMorgan.
07:51 EDTSHPGShire raises FY14 adjusted EPS growth view to high 30% range
Shire CEO Flemming Ornskov said, "Our early and late stage pipeline continues to be strengthened, both internally, and through business development providing us with new investments in Ophthalmology and Rare Diseases. The FDA accepted with priority review our supplemental new drug application for VYVANSE as a treatment for adults with binge eating disorder and we expect to learn about the potential expanded indication in February 2015. Our strong momentum and performance this quarter is evidence of our ability to deliver growth, efficiency and innovation through our commitment to addressing significant unmet need in Rare Diseases and high-value specialty conditions. As a result, I am pleased to once again increase our guidance for 2014. We now expect to deliver Non GAAP diluted earnings per ADS growth in the high thirty percent range in 2014.”
07:50 EDTSHPGShire repeats commitment to double products sales to $10B by 2020
Shire Chairman Susan Kilsby said: “Shire is well-positioned for future growth as we implement our plan to double product sales to $10B by 2020. I am confident that Shire, as an independent company, will deliver long-term value to our shareholders and improved outcomes for patients. On behalf of the Board of Directors, I would like to thank the Shire management team and employees for the achievement of outstanding financial results during the third quarter.”
07:49 EDTSHPGShire reports Q3 EPS $2.93, consensus $2.48
Subscribe for More Information
07:35 EDTBMYBristol-Myers reports Q3 Eliquis revenue $216M
Reports Q3 Baraclude revenue $325M, Sprycel revenue $385M, Yervoy revenue $350M. Reports Q3 Abilify revenue $449M, Orencia revenue $444M.
07:33 EDTBMYBristol-Myers confirms FY14 adjusted EPS view $1.70-$1.80, consensus $1.78
Cuts FY14 GAAP EPS view to $1.15-$1.25 from $1.50-$1.60. Both GAAP and non-GAAP guidance assume current exchange rates and that the R&D tax credit will be extended by Congress in 2014. Sees FY14 worldwide revenue $15.2B-$15.8B, consensus $15.58B. Also sees: Full-year gross margin as a percentage of revenues between 75% and 76%. Advertising and promotion expense decreasing in the mid-teen-digit range. Marketing, sales and administrative expenses decreasing in the mid-single-digit range. Research and development expenses growing in the mid-single-digit range. An effective tax rate of 19% - 20%.
07:31 EDTBMYBristol-Myers reports Q3 adjusted EPS 45c, consensus 42c
Subscribe for More Information
07:19 EDTCELGCelgene pipeline could double market cap in 3-5 years, says Deutsche Bank
Deutsche Bank raised its price target for Celgene shares to $134 from $115 following the company's Q3 results saying its pipeline could potentially double the market capitalization over the next 3-5 years. Deutsche views Celgene's pipeline as "the most transformative in biotech" and keeps a Buy rating on the stock.
07:18 EDTCELGCelgene price target raised to $117 from $104 at JMP Securities
Subscribe for More Information
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use